Official ESCRS | European Society of Cataract & Refractive Surgeons
London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Relationship between mean platelet volume

Poster Details

First Author: E.Çinici TURKEY

Co Author(s):                  

Abstract Details


Objectives To evaluate the effect of mean platelet volume(MPV) and mean erythrocyte volume(MEV) on diabetic retinopathy in patients with type 2 diabetes mellitus.


Erzurum Regional Training and Research Hospital, Department of Ophtalmology, Turkey


In this study, ocular findings and MPVand MEV alues were retrospectively reviewed in 104 patients with type 2 diabetes mellitus. The patients were classified into four groups according to ocular findings, as follows: group 1, diabetic patients without diabetic retinopathy (n =70); group 2, diabetic patients with non-proliferative diabetic retinopathy (n =64); group 3, diabetic patients with proliferative diabetic retinopathy (n =58); and group 4, healthy controls (n =100).


A significant difference was found in MPV values between groups 2 and 4 (P =0.001), between groups 3 and 4 (P =0.001), and between groups 1 and 4 (P =0.002). The three diabetic groups (groups 1, 2, and 3) were compared with each other. While there was a statistically significant difference between groups 1 and 3 (P =0.015), there was no significance between groups 2 and 3 (P =0.46), and between group 1 and 2 (P =0.241). There was no statistically significant difference between the groups in terms of MCV


In diabetic patients, the risk of retinopathy development increases with higher MPV values. There was no correlation between the development of retinopathy with MCV.

Financial Disclosure:


Back to Poster listing